Wed, Jul 30, 2014, 6:26 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman May 6, 2013 1:37 PM Flag

    New Amgen-IMGN compounds in phase I

    I learned from the recent AVEO, Tivo FDA debacle, there are several approved drugs for RCC that work OK, but only for a limited time and with harsh side effects. There's room for improvement in efficacy and safety with blockbuster potential in this indication. The ONXX drug sells over $1BB and is not all that efficacous, so there's room for improvement and large profits.

    I doubt anything works for Glioma, so the hurdle should be low, maybe AMGN can get on a very fast track/breakthrough.

    AMG 595 - This TAP compound, in development by Amgen, is in Phase I clinical testing for recurrent malignant glioma.
    AMG 172 - This TAP compound, in development by Amgen, is in Phase I clinical testing for clear cell renal cell carcinoma (ccRCC).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMGN
11.11+0.16(+1.46%)Jul 30 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.